Oncologix Tech, Inc.
OCLG · OTC
11/30/2022 | 8/31/2022 | 11/30/2017 | 8/31/2017 | |
|---|---|---|---|---|
| Revenue | $0 | – | $1 | $1 |
| % Growth | – | – | -11.9% | – |
| Cost of Goods Sold | $0 | – | $0 | $1 |
| Gross Profit | $0 | – | $0 | $0 |
| % Margin | – | – | 23.3% | 14.6% |
| R&D Expenses | $0 | – | $0 | $0 |
| G&A Expenses | $0 | – | $0 | $0 |
| SG&A Expenses | $0 | – | $0 | $0 |
| Sales & Mktg Exp. | $0 | – | $0 | $0 |
| Other Operating Expenses | $0 | – | $0 | $0 |
| Operating Expenses | $0 | – | $0 | $0 |
| Operating Income | -$0 | – | -$0 | -$0 |
| % Margin | – | – | -9.5% | -51.4% |
| Other Income/Exp. Net | -$0 | – | -$0 | -$1 |
| Pre-Tax Income | -$0 | – | -$0 | -$1 |
| Tax Expense | $0 | – | $0 | $0 |
| Net Income | -$0 | – | -$0 | -$1 |
| % Margin | – | – | -37.3% | -184.4% |
| EPS | -0 | – | -0 | -0.002 |
| % Growth | – | – | 83.3% | – |
| EPS Diluted | -0 | – | -0 | -0.002 |
| Weighted Avg Shares Out | 1,662 | – | 773 | 737 |
| Weighted Avg Shares Out Dil | 1,662 | – | 773 | 737 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | – | $0 | $0 |
| Interest Expense | $0 | – | $0 | $1 |
| Depreciation & Amortization | $0 | – | $0 | $0 |
| EBITDA | -$0 | – | -$0 | -$1 |
| % Margin | – | – | -10% | -87.9% |